CJC-1295 Peptide: Structure, Combinations, and Research Applications
All products sold by Polaris Peptides are intended solely for chemical research and laboratory applications. Our peptides are for scientific purposes only and are not intended for use in humans, animals, or any other form of in vivo research. We strictly adhere to the highest standards of purity and quality for our products, but they are to be utilized exclusively within a controlled laboratory environment for chemical research.
CJC-1295 peptide is a synthetic analog of growth hormone–releasing hormone (GHRH) that has become a cornerstone in experimental models exploring endocrine modulation, growth hormone (GH) regulation, and the IGF-1 signaling axis (Teichman et al.). Unlike native GHRH, which is rapidly broken down in circulation, CJC-1295 is engineered for enhanced stability and bioactivity, allowing researchers to study sustained and pulsatile GH release over a longer period (Ionescu & Frohman).
Growth hormone plays a critical role in tissue repair, muscle preservation, metabolic balance, and immune regulation (Sackmann-Sala et al.). However, direct GH administration can disrupt feedback mechanisms and lead to supraphysiological exposure. CJC-1295 offers an alternative approach by stimulating endogenous GH secretion, preserving the natural pulsatile rhythm that is essential for downstream effects without suppressing the body’s internal signaling systems (Van Hout & Hearne).
The interest in CJC-1295 peptide extends across multiple research domains – from studies on age-related hormone decline to protocols focused on muscle regeneration, immune support, and metabolic enhancement (Henninge et al.). Whether used alone or in combination with complementary peptides like Ipamorelin, CJC-1295 remains one of the most widely studied tools for researchers investigating the growth hormone–IGF-1 axis.
In this article, we’ll explore what CJC-1295 is, how it works, and how it fits into advanced peptide research.
What Is CJC-1295?
CJC-1295 is a tetrasubstituted GHRH analog designed to enhance the stability and bioactivity of native GHRH (Teichman et al.). It is most commonly studied in its DAC-free form (no Drug Affinity Complex), which promotes shorter but more physiologically mimetic GH pulses. This version is preferred in experimental contexts where natural GH oscillation is important for modeling biological processes (Ionescu & Frohman).
CJC-1295 binds to GHRH receptors on the anterior pituitary gland, triggering the release of growth hormone, which in turn promotes the production of insulin-like growth factor 1 (IGF-1) in the liver (Sackmann-Sala et al.). This axis regulates a wide range of processes, including muscle repair, metabolism, immune modulation, and tissue regeneration (Van Hout & Hearne).
Mechanism of Action
The mechanism of action of CJC-1295 peptide centers on its function as a GHRH analog. By binding to GHRH receptors in the pituitary, it triggers the release of endogenous GH in a manner that closely mimics natural secretion patterns (Ionescu & Frohman).
Key features of CJC-1295’s mechanism include:
Pulsatile GH Secretion:
Stimulates periodic GH bursts, preserving circadian rhythm and receptor sensitivity, an advantage over constant GH exposure (Teichman et al.).
Increased IGF-1 Production:
GH release from the pituitary promotes hepatic synthesis of IGF-1, a mediator involved in tissue repair, cellular growth, and anabolism (Sackmann-Sala et al.).
Non-Disruptive Feedback Loop:
Unlike exogenous GH, which may suppress natural production, CJC-1295 supports a feedback-preserving approach, allowing for endocrine balance in research models (Van Hout & Hearne).
Shorter Half-Life (No DAC):
CJC-1295 without DAC remains active for a few hours, making it suitable for studies that prioritize physiological hormone rhythms over prolonged exposure (Henninge et al.).
Want to explore the biochemical structure and mechanisms in more detail? Read:
Combining CJC-1295 with Other Peptides
One of the most common approaches in growth hormone research involves combining CJC-1295 peptide with other peptides that act through different pathways. While CJC-1295 targets the GHRH receptor to stimulate growth hormone release (Ionescu & Frohman), it can be paired with peptides that work through the ghrelin (GHS-R1a) receptor or other endocrine targets, leading to synergistic GH output and broader biological activity in experimental models (Teichman et al.; Van Hout & Hearne).
CJC-1295 + Ipamorelin
This is perhaps the most widely studied combination. Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R1a) agonist, which stimulates GH release by suppressing somatostatin, the body’s natural GH inhibitor (Teichman et al.). When used alongside CJC-1295, which promotes GH secretion through direct pituitary stimulation, the result is a dual-pathway approach that enhances both the magnitude and duration of GH pulses (Ionescu & Frohman). This pairing is commonly used in studies investigating muscle growth, fat metabolism, and recovery following tissue stress (Van Hout & Hearne).
If you want to learn more about the combination of CJC-1295 and Ipamorelin, check out our article:
CJC-1295 + Tesamorelin
While both CJC-1295 and Tesamorelin are GHRH analogs, they differ structurally and in their half-life. Tesamorelin has shown unique promise in reducing visceral adipose tissue, particularly in metabolic disease models (Teichman et al.). Research comparing these peptides explores their differences in GH stimulation profiles, metabolic effects, and IGF-1 response (Ionescu & Frohman). When evaluated side by side or in tandem, these compounds provide insight into how variations in GHRH analog design influence biological outcomes (Van Hout & Hearne).
To explore the differences between CJC-1295 and Tesamorelin in more detail, check out our comparison article:
Applications and Research Potential
CJC-1295 peptide continues to be explored across a wide range of experimental domains thanks to its ability to stimulate pulsatile growth hormone release and downstream IGF-1 signaling (Teichman et al.). These mechanisms make it especially valuable in models focused on muscle repair, neuroprotection, immune modulation, and metabolic resilience (Sackmann-Sala et al.; Ionescu & Frohman).
1. Muscle Repair and Recovery
One of the most well-established applications of CJC-1295 peptide in experimental research is its role in muscle regeneration and recovery. Growth hormone and its downstream mediator, insulin-like growth factor 1 (IGF-1), are essential for maintaining skeletal muscle integrity (Teichman et al.). In injury and atrophy models, GH signaling has been shown to support satellite cell activation, enhance protein synthesis, and stimulate myoblast proliferation, all of which contribute to tissue regeneration (Sackmann-Sala et al.).
CJC-1295 promotes endogenous GH release in a pulsatile manner, which is particularly important for muscle recovery, as physiologic GH pulses align with periods of repair during sleep and post-exercise recovery (Ionescu & Frohman). This peptide has been studied in both acute and chronic recovery scenarios, including models of post-surgical healing, exercise-induced microtrauma, and age-related sarcopenia (Van Hout & Hearne). Additionally, IGF-1 produced downstream can aid in collagen synthesis and connective tissue remodeling, making CJC-1295 relevant not only for muscle tissue but for tendons and ligaments as well (Henninge et al.).
Overall, this makes CJC-1295 a valuable candidate in experimental protocols focused on regenerative capacity, mobility, and tissue resilience, particularly in models simulating physiological stress or age-related decline.
2. Neurological and Cognitive Function
GH and IGF-1 are also active in the central nervous system, where they are believed to influence neurogenesis, synaptic plasticity, and protection against neurodegenerative changes (Sackmann-Sala et al.). CJC-1295 is being studied in models addressing brain aging and cognitive decline (Teichman et al.; Ionescu & Frohman).
If you want to learn more about the role of peptides in brain health and neurodegenerative research, visit:
👉 Peptides in Neurodegenerative Disease and Brain Health
3. Immune System Support and Oncology Research
Research has also connected GH signaling to immune function, particularly through its impact on thymic regeneration and T-cell maturation (Teichman et al.). CJC-1295 is included in certain immunological and oncological peptide research models for its potential to support immune homeostasis (Ionescu & Frohman; Van Hout & Hearne).
If you want to learn more about the intersection of peptides and cancer immunotherapy, check out:
👉 Peptides in Cancer Immunotherapy
4. Cardiovascular Research and Metabolic Health
Because GH affects lipid metabolism, endothelial function, and cardiovascular remodeling, CJC-1295 may have a place in models of vascular aging, hypertension, and cardiometabolic disease (Teichman et al.; Ionescu & Frohman; Sackmann-Sala et al.).
If you want to learn more about how peptides are being designed to support cardiovascular health, see:
👉 Designing Peptides for Cardiovascular Health
Across these areas, CJC-1295 peptide remains a foundational tool in endocrine and regenerative peptide science, enabling targeted investigations into GH-regulated pathways that support systemic function, recovery, and healthy aging.
Where to Find Research-Grade CJC-1295
For investigators working in the field of peptide endocrinology, Polaris Peptides provides high-quality CJC-1295 (no DAC), rigorously tested for purity, identity, and stability. Our peptides are prepared under controlled conditions and are intended strictly for non-human, preclinical, or in vitro research applications.
Polaris remains committed to supporting scientific discovery through reliable and reproducible peptide supply.
Conclusion
As a longer-acting GHRH analog, CJC-1295 peptide has opened new avenues in experimental research related to hormone regulation, aging, recovery, and metabolic optimization. Its ability to sustain endogenous GH release while preserving physiological feedback loops makes it a preferred tool for researchers studying the GH–IGF-1 axis without disrupting endocrine homeostasis.
When combined with peptides like Ipamorelin, or applied in targeted recovery models, CJC-1295 continues to demonstrate value as a flexible and physiologically relevant compound in modern peptide science. For high-quality, research-grade CJC-1295, Polaris Peptides offers rigorously tested material to support advanced, non-clinical studies.